Uncategorized
Eleven Biotherapeutics, Roche enter exclusive license agreement for IL-6 antagonist antibody technology
Eleven Biotherapeutics has entered into an exclusive license agreement with Roche to develop and commercialize EBI-031 and other IL-6 antagonist antibody technology owned by Eleven, according to a press release. Under the terms of the agreement, Eleven will eligible for an upfront payment of $7.5 million and potential milestone payments of up to $262.5 million, as well as royalties for net sales of future products containing EBI-031 or other IL-6 compounds.